OR WAIT 15 SECS
Valerie DeBenedette is managing editor of Drug Topics.
A new rule in Ohio is designed to bring transparency to drug prices in the pharmacy.
The Ohio Department of Insurance has told PBMs and health insurers that they have to disclose the lowest price for a prescription drug to patients and prohibits them from charging more for prescription drugs that cost less than the copay. The department has also banned the gagging of pharmacists by contractually preventing them from telling patients they could pay less out of pocket for a drug than the insurance copay.
There had been many examples of egregious clawbacks in Ohio, says Antonio Ciaccia, using the term to describe the overcharging of the patient and the later collection of some of that overcharge by the PBM. Ciaccia is director of government and public affairs for the Ohio Pharmacists Association.
In testimony to a committee of the Ohio House of Representatives, Chiaccia gave an example:
“For a medication used to treat severe vitamin deficiency, the pharmacy’s cash price was $92. The pharmacy processed the claim and was told to charge the patient $115.19. The PBM later performed a $55.47 clawback. So in the end, the patient was overcharged $23.19, the pharmacy lost $32.28, and the PBM pocketed it all. And again, while this was occurring, the pharmacist was prohibited in their contract from blowing the whistle on the charade, and helping the patient find a cheaper alternative method of payment.”
Preventing pharmacists from informing their patients about drug prices is a serious matter, Ciaccia told the committee. “Pharmacists should not be silent pawns in drug pricing shell games, and should be free to discuss all options for the patient at the pharmacy counter-including whether or not there are ways to save money on their needed medications.”
Related article: Pharmacists Are the Vitamins of Healthcare
The results of the ruling from the insurance department is an immediate lowering of drug copays, Ciaccia tells Drug Topics. “Ultimately, the Ohio Department of Insurance acted once they learned how pervasive the problem of clawbacks was,” he says. The Ohio legislature had been making an effort to prohibit the practice of charging a higher copay than the actual price of a drug, which gave the insurance department the impetus to act, he adds.
Other states have enacted similar rules or are considering legislation to increase drug price transparency. “There seems to be a universal gag reflex by lawmakers who learn about co-pay clawbacks and mandated silence of pharmacists,” says Ciaccia. “The practices are so distasteful that even the PBMs’ own association won’t stand up for them.”
Two large PBMs-Express Scripts and CVS Caremark-told Reuters that their contracts include clauses that ensure that members receive the lowest drug price automatically.
On the federal level, two bills have been introduced that are aimed at making drug pricing transparent to consumers and preventing gag clauses.
The legality of such gag clauses has always been questionable, Ciaccia adds, since they are the subject of several lawsuits across the country. “Theoretically, plans and PBMs could still penalize pharmacists for pushing back and blowing the whistle on non-compliance with the new rules, but ultimately, if PBMs ignore these new policies, they stand to be fined or having their licenses suspended by the Ohio Department of Insurance. Personally, I think the ODI edict ... will end these shenanigans for good.”